Danaher Corporation $DHR Shares Sold by RWA Wealth Partners LLC

RWA Wealth Partners LLC reduced its position in shares of Danaher Corporation (NYSE:DHR) by 49.9% during the first quarter, Holdings Channel.com reports. The fund owned 6,445 shares of the conglomerate’s stock after selling 6,411 shares during the quarter. RWA Wealth Partners LLC’s holdings in Danaher were worth $1,321,000 at the end of the most recent reporting period.

Other hedge funds have also recently bought and sold shares of the company. FAS Wealth Partners Inc. boosted its position in shares of Danaher by 20.6% in the 4th quarter. FAS Wealth Partners Inc. now owns 9,597 shares of the conglomerate’s stock valued at $2,203,000 after purchasing an additional 1,639 shares during the period. MGO One Seven LLC boosted its position in shares of Danaher by 485.7% in the 1st quarter. MGO One Seven LLC now owns 25,098 shares of the conglomerate’s stock valued at $5,145,000 after purchasing an additional 20,813 shares during the period. Asahi Life Asset Management CO. LTD. acquired a new position in shares of Danaher in the 1st quarter valued at $539,000. Horizon Financial Services LLC boosted its position in shares of Danaher by 20,400.0% in the 1st quarter. Horizon Financial Services LLC now owns 8,200 shares of the conglomerate’s stock valued at $1,681,000 after purchasing an additional 8,160 shares during the period. Finally, EFG Asset Management Americas Corp. boosted its position in shares of Danaher by 13.1% in the 1st quarter. EFG Asset Management Americas Corp. now owns 36,080 shares of the conglomerate’s stock valued at $7,396,000 after purchasing an additional 4,191 shares during the period. 79.05% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on DHR shares. TD Cowen increased their price target on Danaher from $240.00 to $248.00 and gave the company a “buy” rating in a research report on Wednesday, April 23rd. Wells Fargo & Company decreased their price target on Danaher from $210.00 to $205.00 and set an “equal weight” rating for the company in a research report on Wednesday, July 23rd. Deutsche Bank Aktiengesellschaft decreased their price target on Danaher from $240.00 to $235.00 in a research report on Thursday, June 5th. Barclays reiterated an “overweight” rating and issued a $225.00 price target (up previously from $215.00) on shares of Danaher in a research report on Tuesday, June 24th. Finally, Leerink Partners raised their price objective on Danaher from $225.00 to $230.00 and gave the stock an “outperform” rating in a research report on Wednesday, April 23rd. Seventeen analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $247.61.

Danaher Trading Up 1.5%

Shares of NYSE DHR opened at $212.2350 on Wednesday. Danaher Corporation has a one year low of $171.00 and a one year high of $279.90. The firm has a market capitalization of $151.97 billion, a PE ratio of 45.16, a PEG ratio of 2.92 and a beta of 0.73. The company has a current ratio of 1.62, a quick ratio of 1.22 and a debt-to-equity ratio of 0.32. The business has a 50-day moving average price of $200.33 and a two-hundred day moving average price of $199.54.

Danaher (NYSE:DHR) last announced its quarterly earnings data on Tuesday, July 22nd. The conglomerate reported $1.80 EPS for the quarter, topping analysts’ consensus estimates of $1.64 by $0.16. Danaher had a return on equity of 10.70% and a net margin of 14.21%.The firm had revenue of $5.94 billion during the quarter, compared to analyst estimates of $5.83 billion. During the same period last year, the company posted $1.72 EPS. The business’s quarterly revenue was up 3.4% compared to the same quarter last year. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. As a group, analysts predict that Danaher Corporation will post 7.63 earnings per share for the current fiscal year.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.